Disease · MONDO_0019338

sarcoidosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. sarcoidosis. Diseases, record MONDO_0019338. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019338

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: sarcoidosis; Open Targets
Open Targets ID: MONDO_0019338; Open Targets
Other names: BESNIER BOECK DIS, Benign lymphogranulomatosis of Schaumann, Besnier Boeck Disease, Besnier Boeck Schaumann Syndrome, Besnier-Boeck-Schaumann disease, Boeck Disease, Boeck Sarcoid, any site, Boeck sarcoid, Boeck's Disease, Boeck's sarcoid, Boeck's sarcoidosis, Boecks Disease, Boecks Sarcoid, Boecks sarcoidosis, Darier-Roussy sarcoid, Disease, Schaumann, Lupus pernio of Besnier, Miliary lupoid of Boeck, SCHAUMANN DIS, Sarcoid, Boeck's, Sarcoidoses, Sarcoidosis (disorder), Sarcoidosis, NOS, Schaumann Disease, Schaumann Syndrome, Schaumann's Syndrome, Schaumann's Syndromes, Syndrome, Besnier-Boeck-Schaumann, Syndrome, Schaumann, Syndrome, Schaumann's, Uveoparotid fever, lymphogranulomatosis, sarcoid; Open Targets
Disease Ontology: DOID:11335; Disease Ontology
MeSH: D012507; MeSH
NCI Thesaurus: C34995; NCI Thesaurus
Orphanet: ORPHA:797; Orphanet
Highest stage of its drugs: Approval, for 5 of its 45 drugs, from DailyMed and TTD; Open Targets

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	21	5	4	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	43	2	2	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	4	2	1	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	CHEMBL2108709	Enzyme	Approval	TTD	1	0	0	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
HYDROXYCHLOROQUINE	CHEMBL1535	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AVOTERMIN	CHEMBL2108833	Protein	Phase 3	TTD	1	0	0	Drugs and targets
CORTICOTROPIN	CHEMBL1201610		Phase 2/3	ClinicalTrials.gov	2	2	1	Drugs and targets
ARMODAFINIL	CHEMBL1201192	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 45

See all 45 drugs

Targets69

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
TNF	Tumor necrosis factor	3	TNF-alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7124	Drugs and targets
TYK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/7297	Drugs and targets
CCR5	C-C chemokine receptor type 5	1	C-C chemokine receptor type 5 antagonist	Unknown	https://conductscience.org/library/genes/1234	Drugs and targets
CD52	CAMPATH-1 antigen	1	CAMPATH-1 antigen inhibitor	Phase 1/2	https://conductscience.org/library/genes/1043	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	1	T-lymphocyte activation antigen CD80 inhibitor	Phase 2	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	1	T-lymphocyte activation antigen CD86 inhibitor	Phase 2	https://conductscience.org/library/genes/942	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Early phase 1	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Early phase 1	https://conductscience.org/library/genes/1141	Drugs and targets
COL11A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1301	Drugs and targets

1 to 10 of 69

See all 69 targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00955279	A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis	Phase 2	173	2014-07-17	Sarcoidosis	GOLIMUMAB, USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02039687	Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis	Phase 2	64	2017-01-18	Neuropathy of Sarcoidosis	CIBINETIDE	Its record names the disease	ClinicalTrials.gov
NCT02888080	Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis	Phase 2	40	2020-03-16	Pulmonary Sarcoidosis	CANAKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT04008069	Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis	Phase 2	16	2023-10-05	Sarcoidosis	SARILUMAB	Its record names the disease	ClinicalTrials.gov
NCT00311246	Trial of Adalimumab in Progressive Sarcoidosis	Phase 2	11	2020-08-14	Sarcoidosis	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT03793439	Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis	Phase 1	5	2022-02-18	Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis	PREDNISONE, TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT02134717	Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes	Not applicable	3	2017-07-18	Sarcoidosis	MARAVIROC	Its record names the disease	ClinicalTrials.gov
NCT00282438	Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis	Phase 1/2	2	2017-02-24	Sarcoidosis	CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT00739960	Safety Study of Abatacept to Treat Refractory Sarcoidosis	Phase 2	1	2020-03-17	Sarcoidosis	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT05247554	Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis	Phase 3	200		Pulmonary Sarcoidosis	HYDROXYCHLOROQUINE, PREDNISONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ACZ885 300 mg vs Placebo: deaths from any cause	0 of 20	0 of 20	40	NCT02888080	Trial comparisons
ACZ885 300 mg vs Placebo: serious adverse events	3 of 20	4 of 20	40	NCT02888080	Trial comparisons
Double-Blind Sarilumab (Post-randomization) vs Double-Blind Placebo (Post-randomization): Number of Participants Without Sarcoidosis Flare (Flare-Free Survival)	2 of 2	7 of 8	10	NCT04008069	Trial comparisons
Autologous Hematopoietic Stem Cell Transplantation vs Allogeneic Stem Cell Transplantation: Presence of Toxicity	1 of 1	1 of 1	2	NCT00282438	Trial comparisons
Autologous Hematopoietic Stem Cell Transplantation vs Allogeneic Stem Cell Transplantation: Survival	1 of 1	0 of 1	2	NCT00282438	Trial comparisons
Autologous Hematopoietic Stem Cell Transplantation vs Allogeneic Stem Cell Transplantation: serious adverse events	0 of 1	1 of 1	2	NCT00282438	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
18256069	RESULT	1	PubMed
16840744	RESULT	1	PubMed
37690784	DERIVED	1	PubMed
37471590	DERIVED	1	PubMed
35668129	DERIVED	1	PubMed
33825964	DERIVED	1	PubMed
33317858	DERIVED	1	PubMed
25594886	DERIVED	1	PubMed
25428650	DERIVED	1	PubMed
25034562	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019338

GET https://conductscience.org/api/diseases/v1/MONDO_0019338/drugs?page=2

API reference For AI assistants